-40%

HGH 191AA 10 iu x 1 vial – Superior Peptide

Name: HGH 191AA 10 iu x 1 vial – Superior Peptide
SKU: 2635
Price: 2400.00 INR
Availability: InStock

₹2,400.00

Categories: HGH, Peptides, Superior Peptide Tags: Superior peptide, Superior peptide Adipotide (FTPP), Superior peptide AOD, Superior peptide authentic, Superior peptide before and after, Superior peptide BPC-157, Superior peptide BPC-157 + TB-500, Superior peptide buy online, Superior peptide CJC-1295 DAC, Superior peptide fat loss blend, Superior peptide FST-344, Superior peptide gaining blend, Superior peptide GHRP-2 + CJC-1295 + IPAMORELIN, Superior peptide GHRP-6, Superior peptide GHRP-6 + MOD GRF + HEXARELIN, Superior peptide GONADORELIN, Superior peptide HGH 191AA, Superior peptide HGH FRAG + CJC-1295 + IPAMORELIN, Superior peptide HGH-FRAG, Superior peptide IGF-1 LR3, Superior peptide IPAMORELIN, Superior peptide lean gain blend, Superior peptide MOD GRF (1-29), Superior peptide original, Superior peptide PGCL, Superior peptide PT-141, Superior peptide recovery blend, Superior peptide results, Superior peptide ripping blend, Superior peptide side effects, Superior peptide TB-500, Superior peptide TESAMORELIN + CJC-1295 + IPAMORELIN, Superior peptides

Description
Reviews (0)

Description

DESCRIPTION

Superior Peptide HGH is a sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with bacteriostatic water for injection.

U.S.P. PHARMACOLOGY:

In vitro, preclinical, and clinical tests have demonstrated that somatropins are therapeutically equivalent to human growth hormone of pituitary origin and achieve similar pharmacokinetic profiles in normal adults. In pediatric patients who have growth hormone deficiency (GHD), treatment with somatropin stimulates linear growth and normalizes concentrations of Insulin-like Growth Factor -I (IGF-I).In adults with GHD, treatment with somatropin results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations.

PHARMACOKINETICS

Absorption: Following a subcutaneous injection of a single dose of 4 mg Somatotropin in healthy male and female adults, the extent of absorption (AUC) was 291 hr.μg/L and the peak concentration (Cmax) was 37 μg/L. There are no pharmacokinetic data from patients with GHD.

Distribution: The mean volume of distribution of Somatotropin following administration to healthy adults was estimated to be 1.4 L/kg.

Metabolism: The metabolic fate of Somatotropin was not studied. However, it is presumed that the metabolic fate of Somatotropin involves classical protein catabolism in both the liver and kidneys.

Excretion: The mean clearance subcutaneously administered Somatotropin in healthy adults was 0.23 (± 0.04) L/hrkg. The mean terminal half-life of Somatotropin after a single subcutaneous injection in healthy adults is 2.4 hours

INDICATIONS AND USAGE:

HGH is indicated for:

Long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.
Long-term replacement therapy in adults with growth hormone deficiency (GHD) of either childhood- or adult-onset etiology. GHD should be confirmed by an appropriate growth hormone stimulation test.

INDICATIONS AND USAGE:

The dosage of HGH must be adjusted for the individual patient. The weekly dose should be divided into daily subcutaneous injections (administered preferably in the evening). HGH may be given in the thigh, buttocks, or abdomen; the site of SC injections should be rotated daily to help prevent lipoatrophy. Pediatric GHD Patients: Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended. Adult GHD Patients: The recommended dosage at the start of therapy is not more than 0.04 mg/kg/week. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to a maximum of 0.08 mg/kg/week, depending upon patient tolerance of treatment. Clinical response, side effects, and determination of age-adjusted serum IGF-I may be used as guidance in dose titration. This approach will tend to result in weight-adjusted doses that are larger for women compared with men and smaller for older and obese patients.

Reviews

There are no reviews yet.

Be the first to review “HGH 191AA 10 iu x 1 vial – Superior Peptide”

TB-500 (Thymosin Beta-4) 10 mg x 1 vial – Superior Peptide

HGH-FRAG (Fragment 176-191) 6 mg x 1 vial – Superior Peptide

HGH 191AA 10 iu x 1 vial – Superior Peptide